Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome

Molecular and Cellular Endocrinology

Volumn 350, Issue 2, 2012, Pages 273-280

  Shibata, Shigeru ^a,b   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Metabolic syndrome; Mineralocorticoid receptor; Podocytes; Rac1; Salt sensitive hypertension

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; PLACEBO; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SPIRONOLACTONE;

ADIPOCYTE; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; HYPERTENSION; INFLAMMATION; MESANGIUM CELL; METABOLIC SYNDROME X; NEPHRON; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; SALT INTAKE;

ALDOSTERONE; ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; RATS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84856318868     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.018     Document Type: Review

References (74)

1. Afshinnia F., et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol. Dial. Transplant. 2010, 25:1173-1183.
2. Alexander J.W., et al. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg. Obes. Relat. Dis. 2009, 5:237-241.
3. Ando K., et al. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens. Res. 2010, 33:616-621.
4. Bentley-Lewis R., et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J. Clin. Endocrinol. Metab. 2007, 92:4472-4475.
5. Bianchi S., et al. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006, 70:2116-2123.
6. Blasi E.R., et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003, 63:1791-1800.
7. Bochud M., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006, 48:239-245.
8. Bonnet F., et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am. J. Kidney Dis. 2001, 37:720-727.
9. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992, 120:893-901.
10. Calhoun D.A., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
11. Caprio M., et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007, 21:2185-2194.
12. Caprio M., et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 2008, 102:1359-1367.
13. Chapman N., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
14. Chen J., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern. Med. 2004, 140:167-174.
15. Chen J., et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet 2009, 373:829-835.
16. Chrysostomou A., et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 2006, 1:256-262.
17. Cushman W.C., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 2002, 4:393-404.
18. D'Agati V.D., Markowitz G.S. Supersized kidneys: lessons from the preclinical obese kidney. Kidney Int. 2008, 73:909-910.
19. Ehrhart-Bornstein M., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 2003, 100:14211-14216.
20. Feria I., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003, 63:43-52.
21. Fujihara C.K., et al. Chronic inhibition of nuclear factor-kappaB attenuates renal injury in the 5/6 renal ablation model. Am. J. Physiol. Renal Physiol. 2007, 292:F92-F99.
22. Gonzalez E., et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int. 2005, 68:263-270.
23. Goodfriend T.L. Obesity, sleep apnea, aldosterone, and hypertension. Curr. Hypertens. Rep. 2008, 10:222-226.
24. Goodfriend T.L., et al. Aldosterone in obesity. Endocr. Res. 1998, 24:789-796.
25. Goodfriend T.L., et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 1999, 7:355-362.
26. Gorzelniak K., et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J. Hypertens. 2002, 20:965-973.
27. Greene E.L., et al. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 1996, 98:1063-1068.
28. Gregoire F.M., et al. Understanding adipocyte differentiation. Physiol. Rev. 1998, 78:783-809.
29. Ingelsson E., et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007, 116:984-992.
30. Jeon J.H., et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008, 22:1502-1511.
31. Jin S., et al. TNF-alpha/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G928-G937.
32. Kataoka S., et al. 11beta-hydroxysteroid dehydrogenase type 2 is expressed in the human kidney glomerulus. J. Clin. Endocrinol. Metab. 2002, 87:877-882.
33. Kawashima T., et al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J. Cell Biol. 2006, 175:937-946.
34. Kidambi S., et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007, 49:704-711.
35. Kim H., et al. TNF-alpha-induced up-regulation of intercellular adhesion molecule-1 is regulated by a Rac-ROS-dependent cascade in human airway epithelial cells. Exp. Mol. Med. 2008, 40:167-175.
36. Lakka H.M., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
37. Leroy V., et al. Aldosterone activates NF-kappaB in the collecting duct. J. Am. Soc. Nephrol. 2009, 20:131-144.
38. Lin S., et al. Spironolactone ameliorates podocytic adhesive capacity via restoring integrin alpha 3 expression in streptozotocin-induced diabetic rats. J. Renin Angiotensin Aldosterone Syst. 2010, 11:149-157.
39. Lombes M., et al. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1994, 135:834-840.
40. Masuzaki H., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2166-2170.
41. Mehdi U.F., et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 2009, 20:2641-2650.
42. Nagai Y., et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 2005, 46:1039-1045.
43. Nagase M., et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50:877-883.
44. Nagase M., et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
45. Nagase M., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 2006, 17:3438-3446.
46. Nguyen Dinh Cat A., et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J. 2010, 24:2454-2463.
47. Nishiyama A., et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005, 45:710-716.
48. Penfornis P., et al. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E386-E394.
49. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
50. Pitt B., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
51. Pitt B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
52. Quinkler M., et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005, 112:1435-1443.
53. Quiroz Y., et al. Apoptosis and NFkappaB activation are simultaneously induced in renal tubulointerstitium in experimental hypertension. Kidney Int. Suppl. 2003, S27-S32.
54. Rickard A.J., et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54:537-543.
55. Ritz E., et al. Is there an obesity-metabolic syndrome related glomerulopathy?. Curr. Opin. Nephrol. Hypertens. 2011, 20:44-49.
56. Rocchini A.P., et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 1989, 321:580-585.
57. Rondinone C.M., et al. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 1993, 132:2421-2426.
58. Rossi G.P., et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006, 48:232-238.
59. Rossi G.P., et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 2008, 93:2566-2571.
60. Sato A., Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J. Hum. Hypertens. 2010, 24:387-394.
61. Schwimmer J.A., et al. Secondary focal segmental glomerulosclerosis in non-obese patients with increased muscle mass. Clin. Nephrol. 2003, 60:233-241.
62. Shibata S., et al. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J. Am. Soc. Nephrol. 2006, 17:754-764.
63. Shibata S., et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364.
64. Shibata S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat. Med. 2008, 14:1370-1376.
65. Takai Y., et al. Small GTP-binding proteins. Physiol. Rev. 2001, 81:153-208.
66. Takase O., et al. NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria. Kidney Int. 2005, 68:464-473.
67. Terada Y., et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J. Am. Soc. Nephrol. 2005, 16:2296-2305.
68. Trachtman H., et al. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J. Urol. 2004, 172:1590-1594.
69. Usher M.G., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 2010, 120:3350-3364.
70. Verhave J.C., et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J. Intern. Med. 2004, 256:324-330.
71. Williams G.H., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 2004, 93:990-996.
72. Wu X., et al. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 2008, 133:340-353.
73. Zannad F., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 364:11-21.
74. Zennaro M.C., et al. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J. Clin. Invest. 1998, 101:1254-1260.